Mene pangalos, British neuroscientist

London, Feb 11 Pharmaceutical company AstraZeneca said it could take between six to nine months to produce Covid-19 vaccines that are effective against new variants of the virus.A six-month turnaround for an updated vaccine would represent a vast improvement over traditional vaccine development timelines, The Guardian reported on Thursday."Work on the variants hasn't started today, it started weeks and months ago, as soon as those new variants were identified and... we are aiming to be in the clinic in the spring, with next generation vaccines for the new variants," said Sir Mene Pangalos, Executive Vice-President, BioPharmaceuticals R&D at AstraZeneca.Pangalos added that the jabs could be available to the public by the autumn, assuming the regulatory bodies are satisfied with using studies into the body's immune response to the vaccine as the route to approval.The company's vaccine, developed jointly with the University of Oxford, remains effective against the original virus and at least one variant, first discovered in Kent, England. But preliminary findings in a small-scale trial prompted South Africa to limit its use while it ascertains its efficacy against the variant that emerged there, the report said.A number of Covid vaccines have shown lower efficacy in trials where the South Africa variant predominates earlier this week preliminary trials revealed the Oxford-AstraZeneca jab provided little protection against mild to moderate infection, although it is still expected to protect against severe disease and death.It has recently emerged that some cases of the Kent variant have a mutation also found in the South African variant, a development that scientists have cautioned needs to be taken seriously, not least since the mutation known as E484K has been linked to the ability for the South African variant to evade protection offered by some current Covid vaccines, the report said.Panaglos said tests need to be carried out on the Kent variant with the E484K mutation.( With inputs from IANS )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Lok Sabha Election 2024

Heatwave In India

Mumbai Water Cut

Maharashtra Lok Sabha Election

IPL 2024

Salman Khan

Mene PangalosFOLLOW

Mene pangalos, Latest News

Health :AstraZeneca 3rd dose increases antibody response against Omicron

London, Jan 13 A third dose of AstraZeneca's Covid vaccine, named Covishield in India, increases antibody response to ... ...

National :AstraZeneca says its antibody drug Evusheld can fight Omicron variant

London, Dec 24 British-Swedish drugmaker AstraZeneca has announced that its antibody drug 'Evusheld' is effective against the new ... ...

Health :AstraZeneca's antibody cocktail can prevent, treat Covid-19

London, Oct 11 AstraZeneca's long-acting antibody combination is both able to prevent and treat Covid-19, according to the ... ...

Health :AstraZeneca does not raise high blood clot risk post 2nd dose: Study

London, July 29 The incidence of rare blood clot is higher following a Covid-19 infection than two doses ... ...

Health :AstraZeneca monoclonal antibody therapy fails to prevent Covid symptoms

London, June 15 British-Swedish biopharmaceutical company AstraZeneca on Tuesday stated that its monoclonal antibody treatment failed to prevent ... ...

Health :Vaccine against new Covid variants may take 6-9 months: AstraZeneca

London, Feb 11 Pharmaceutical company AstraZeneca said it could take between six to nine months to produce Covid-19 ... ...